Riad SHERIF’s Post

Simplifying the complexities of ocular disease states for over 40 years, Ora's renowned ophthalmology scales are the gold standard for precisely quantifying the qualitative signs and symptoms of vision-impairing conditions across all therapeutic areas. These scales continue to efficiently expedite our client's clinical programs, contributing to an unrivaled 85+ product approvals.   To learn more about how Ora scales deliver clinically meaningful data to fast-track the path to approval, reach out to our team at BD@oraclinical.com. #ophthalmology #translationalresearch #clinicalresearch

Join the All Star Panelists, Arshad M. Khanani; Firas M. Rahhal, MD; Ram Palanki; George Magrath; and Maryam Mokhtarzadeh, M.D. at the Association for Research in Vision and Ophthalmology (ARVO) Special Interest Group (SIG) discussion on "Oral Medications for Management of Retinal Diseases". The session is being moderated by Charles DeBoer and myself. With many attempts to address to treatment burden for both patients and clinicians, oral medications appear to have become a significant focus as a likely treatment option for retinal diseases. This SIG will discuss the various programs and the background information about what it takes to plan and implement an oral med clinical study, various endpoints, what the regulators are likely to look at for approval, and what will it take to commercialize and market these products if and when they get approved. We also encourage the audience to partake in the discussion - we welcome questions and will raise these questions in front of the panel during the SIG. Feel free to ask any questions you may have. Join us for this interesting conversation - the SIG is on July 11, 2024, 3-430pm PST. If you haven't registered, please do so quickly. The panel and the moderators are looking forward to this event!

Did you know that NaturalVue® Enhanced Multifocal 1 Day Contact Lenses may be effective for myopic patients with astigmatism? VTI’s Executive Director of Medical Affairs, Dr. Doug Benoit, says the reason for this comes from the lens design. “The NaturalVue Multifocal lens has a catenary curve-based design, which has a rapid increase in plus power, and that creates a very long and thin extended depth of focus channel,” said Dr. Benoit. “NaturalVue Multifocal can correct any astigmatism that falls along the extended depth of focus channel based on published clinical data.”¹˒² To further understand how NaturalVue® helps address astigmatism, Review of Myopia Management reached out to three practitioners — Dr. Elise Kramer, Dr. Jonathan Chen, and Dr. Jeffrey Cooper. Read about their experiences in this recent: https://lnkd.in/eYUhvTzp #VTI #NaturalVueEnhancedMultifocal #Astigmatism 1. Cooper J, O'Connor B, Aller T, Dillehay SM, Weibel K, Benoit D. Reduction of Myopic Progression Using a Multifocal Soft Contact Lens: A Retrospective Cohort Study. Clin Ophthalmol. 2022 Jul 4;16:2145-2155. 2. Lederman, CR. Myopia Control With Extended Depth of Focus Multifocal Contact Lenses. In: American Association for Pediatric Ophthalmology and Strabismus; 2023 Mar 29; New York, USA. MKT-VTI-SM54 r5

Did you know that NaturalVue® Enhanced Multifocal 1 Day Contact Lenses may be effective for myopic patients with astigmatism? VTI’s Executive Director of Medical Affairs, Dr. Doug Benoit, says the reason for this comes from the lens design. “The NaturalVue Multifocal lens has a catenary curve-based design, which has a rapid increase in plus power, and that creates a very long and thin extended depth of focus channel,” said Dr. Benoit. “NaturalVue Multifocal can correct any astigmatism that falls along the extended depth of focus channel based on published clinical data.”¹˒² To further understand how NaturalVue® helps address astigmatism, Review of Myopia Management reached out to three practitioners — Dr. Elise Kramer, Dr. Jonathan Chen, and Dr. Jeffrey Cooper. Read about their experiences in this recent: https://lnkd.in/eYUhvTzp #VTI #NaturalVueEnhancedMultifocal #Astigmatism 1. Cooper J, O'Connor B, Aller T, Dillehay SM, Weibel K, Benoit D. Reduction of Myopic Progression Using a Multifocal Soft Contact Lens: A Retrospective Cohort Study. Clin Ophthalmol. 2022 Jul 4;16:2145-2155. 2. Lederman, CR. Myopia Control With Extended Depth of Focus Multifocal Contact Lenses. In: American Association for Pediatric Ophthalmology and Strabismus; 2023 Mar 29; New York, USA. MKT-VTI-SM54 r5

Transformative Glaucoma Research Now Available in New Zealand - Glaucoma NZ partnered with the Vision Research Foundation, to present an exclusive insight into groundbreaking glaucoma research led by Professor Jamie Craig. #SAScienceAwards Glaucoma NZ Trust Chair & Scientific Director of Vision Research Foundation Professor Helen Danesh-Meyer, CNZM, MBChB, MD, PhD, FRANZCO says, “I think it’s a fantastic example of scientific discovery making a clinical impact.” Professor Craig from Aledlaide presented his pioneering work, in the development of a polygenic risk score (PRS) known as SightScore™. This score is the first clinically available polygenic score for glaucoma and is now accessible to New Zealanders. What is SightScore™? SightScore™ amalgamates numerous common genetic variants into an easy-to-understand score, placing individuals on a risk continuum for developing glaucoma. This innovation offers New Zealanders a new way to understand their glaucoma risk over their lifetime and the lifetime of their loved ones, which is particularly crucial due to the hereditary nature of glaucoma. Benefits for New Zealand Patients The SightScore™ test helps identify high-risk individuals early, potentially before any symptoms or significant visual field loss occur. This early detection allows clinicians to personalize patient management strategies, from monitoring to deciding on interventions like surgery or laser treatments. Availability for Families It is available through ophthalmologists and optometrists in New Zealand. It requires a simple saliva sample, which is sent to Seonix Bio labs in Australia. An accredited report is then sent back to the referring clinician within four to six weeks. Professor Craig emphasized, "Our science is now in the clinic, and the SightScore™ test will be available in New Zealand from now on." The test is privately paid and costs approximately $349.00 in Australia. This transformative research and its practical application in New Zealand mark a significant step forward in glaucoma management and patient care. #GlaucomaResearch #SightScore #VisionResearch #EyeHealth #GeneticTesting #NewZealandHealth #Ophthalmology #Optometry #EarlyDetection #PersonalizedMedicine #HealthInnovation #GlaucomaAwareness #ProfessorJamieCraig #VisionCare #MedicalBreakthrough #PreventativeHealth #GeneticRisk #EyeCare #VisionFoundation #HealthScience

📈Is A.I. the future of Healthcare? Ophthalmology says yes!👁 Optomed Plc & AEYE Health have received FDA clearance to market and sell their proprietary AI powered handheld fundus camera. Juho Himberg, CEO of Optomed described this milestone as a significant advancement within the care/diagnosis of diabetic retinopathy, the leading care of vision loss in working age-adults. Zack Dvey-Aharon, CEO of AEYE shared their excitement, viewing this collaboration as a demonstration of the power that partnership holds in enabling innovation within healthcare. Topcon Healthcare and RetiSpec announced a collaboration to integrate Retispec's A.I. powered eye diagnostics for Alzheimer's into their Harmony platform. While this integration is limited to test purposes, it will assist in accelerating development/commercialisation. This marks a continued trend in A.I. partnerships from Topcon. In 02/23 Topcon partnered with OphtAI to integrate their ophthalmic AI algorithm into their EMEA business. Further, in 04/23 the organization co-financed Toku Eyes Series A funding round to accelerate commercialisation of their algorithms for retinal-detection of cardiovascular disease. Finally, Xenon Ophthalmics have announced a partnership with visuSolution GmbH. Zeshan Khan, CEO/Founder of Xenon Ophthalmic described the strategic collaboration as vital for enabling access for their telehealth solution across Europe. #ophthalmology #diabeticretinopathy #medicaldevices #artificialintelligence

🎥 Join us for an enlightening discussion featuring Dr. Kenneth Fan (Retina Consultants of Texas), as he delves into the impactful benefits of Bayer | Ophthalmology aflibercept 8mg, at the COPHy Congress. Learn from Dr. Fan's firsthand experiences on how this innovative treatment is revolutionizing care for patients with challenging retinal diseases, offering new hope by reducing treatment frequency and improving their quality of life. Discover the critical role of aflibercept 8mg in managing conditions like recalcitrant disease, and how it's making a significant difference in both patient outcomes and clinical practice efficiency. #COPHY2024 #BayerOphthalmology #8mg #retina #glaucoma #surgicalretina #uveitis #neuropathy #OphthalmologyInsights #MedicalInnovation

😮Exciting Medical Breakthrough! 👨⚕️👩⚕️ Get ready to dive into a groundbreaking case study by Ahmed Basuoni, Sameera Khatri, Yasir Al-Malki, and Marwa Makhlouf! They're unraveling the complexities of pneumopericardium, a rare but severe medical emergency that occurs when air gets trapped in the pericardial sac. 🫀 🛑 This condition can lead to hemodynamic instability, making immediate and multidisciplinary medical intervention crucial. The case report details the journey of a 65-year-old male with advanced pancreatic cancer who faced this complication post-surgery. 🏥 🔎 The diagnosis was made through multimodal imaging, including chest X-ray, echocardiography, and computed tomography. The study underscores the importance of immediate and multidisciplinary medical intervention in such cases. ⏰ 🔗 Don't miss out on this insightful read! Explore the full case study here: https://lnkd.in/gtaHUb8S #MedicalCaseStudy #Pneumopericardium #PancreaticCancerComplications #MultidisciplinaryCare #CardiologyUpdates

We are thrilled to announce that our recent abstracts presented at #ARVO2024 have been published in the Investigative Ophthalmology & Visual Science 2024 Abstract Issue. 🎉 Our two groundbreaking abstracts, titled "Tear Fluid Proteomic Analysis with Improved LC-MS/MS Protocol" and "Quantitative Measurement of Lacritin in the Tear Fluid of Patients with Dry Eye Disease," showcase our team's dedicated efforts to advance tear fluid proteomic analysis. 🧬 These studies highlight our commitment to enhancing diagnostic methods and leveraging tear fluid as a valuable source for diagnosing various ocular conditions. By improving LC-MS/MS protocols and quantifying key biomarkers like lacritin, we are paving the way for more accurate and reliable diagnostic tools for Dry Eye Disease and beyond. 👁️💧 A huge thank you to our incredible team for their hard work and innovation, and to #ARVO2024 for the opportunity to share our research with the global ophthalmology community. 🌍 Stay tuned for more updates on our journey to revolutionize ocular diagnostics! 🚀 #Ophthalmology #MedicalResearch #Proteomics #DryEyeDisease #LCMSMS #TearFluidAnalysis #Innovation #Healthcare

🎥 Take a look at this insightful interview with Dr. Michael Belin, Chief Medical Officer of Epion Therapeutics! At International Keratoconus Academy's Second Annual Keratoconus Symposium, Dr. Belin coached the audience in how to use the 𝗔𝗕𝗖𝗗 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗗𝗶𝘀𝗽𝗹𝗮𝘆 🔠, which he developed to classify disease severity and help diagnose keratoconus earlier. 𝗧𝗵𝗲 𝗕𝗲𝗹𝗶𝗻 𝗔𝗕𝗖𝗗 𝗰𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘂𝘀𝗲𝘀 𝗳𝗼𝘂𝗿 𝗸𝗲𝘆 𝗽𝗮𝗿𝗮𝗺𝗲𝘁𝗲𝗿𝘀 𝘁𝗼 𝗱𝗲𝘁𝗲𝗿𝗺𝗶𝗻𝗲 𝗸𝗲𝗿𝗮𝘁𝗼𝗰𝗼𝗻𝘂𝘀 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻: 🅰 = Anterior radius of curvature 🅱 = Back (posterior radius of curvature) 🅲 = minimal Corneal thickness 🅳 = Distance visual acuity The ABCD Progression Display – available on the OCULUS, Inc. #Pentacam – allows physicians to track the progression of ectatic disease for up to 8 exams. 🩺👁️ This breakthrough could mean earlier detection and treatment with cross-linking, preserving vision for countless patients. 🌟 #Ophthalmology #Innovation #Keratoconus #PatientCare #MedicalAdvances